Rare diseases (RD) encompass a broad spectrum of highly heterogeneous illnesses characterized by a prevalence lower than 1:2000 in general population. Although relatively uncommon, when considered as a whole, these pathologies represent a relevant public health problem.
Introduction
Rare diseases (RD) represent a collective term, including numerous and highly heterogeneous illnesses, which share the peculiarity to affect a limited number of individuals in the population. 1 In particular, the definition of RD in European Union applies for diseases with a prevalence lower than 1:2000 subjects, which accounts for an estimated number of distinct RD between 5000 and 8000. 2 It is important to emphasize that RD do not constitute a defined nosological grouping, as these conditions considerably differ in terms of etiology, clinical features, severity, onset age. Despite such large inhomogeneity, attention to these disorders was focused in the 1970s of the last century and the concept of rare diseases was firstly evidenced, 3, 4 based on the consideration that subjects living with RD usually experience a range of common problems, directly linked to the rarity of these pathologies, including difficult diagnosis, scarce availability of therapeutic options, lack of attention by medical specialists, sense of isolation (Table 1) . 2 Until recently, low awareness has been devoted to the aspects related to RD by a large part of the scientific community and policy makers. 5 Clinical trials, research on pathogenic mechanisms, and epidemiological descriptions are hampered by the very low numbers of cases and their dispersion, as well as by difficulties in amortizing the costs of pharmacological studies. 6 Such scarcity of information often results in disparity in terms of access to care, standardization of healthcare pathways, social support allocations. For these reasons, these pathologies are referred to as orphan diseases. 1, 2, 7 In recent years, however, increasing epidemiological and scientific data pointed out that, despite the rarity of the single disease, when RD are considered collectively, they affect a remarkable portion of the population (at least 13.5 million in European Union), 2 thus becoming a paramount public and social healthcare issue. 1, 5 The pathway of patients with rare disease Patients and families with a rare disease are usually involved in a complex, and often lifelong, healthcare pathway, coming into contact with various types of professional healthcare providers. 8 The paucity of information available in RD impacts at different levels on the healthcare pathway of the affected individual, as well as on family members and caregivers (diagnosis, monitoring, support, therapy, follow-up). Subjects with RD and their families face several hurdles, such as delayed diagnosis, geographical scattering of expertise centers and/or trained professionals, lack of effective therapeutic options, chronic disability trajectories, familial inheritability. 2, 6, 9 Throughout the pathway, the first major barrier experienced by most RD-affected individuals is represented by the diagnostic delay. [9] [10] [11] Several studies have shown that, for many RD, the attainment of a correct diagnosis often entails a delay of many months or even years. Studies performed in hereditary hemorrhagic telangiectasia (HHT), familial mediterranean Fever (FMF), and Ehlers-Danlos syndrome (EDS), reported an average diagnostic delay of 15-25 years. 9,10 A number of factors, including the lack of availability of adequate diagnostic tools, the multidisciplinary nature of the disorder, the prominent phenotypic heterogeneity, and the variability of presentation symptoms, may be evoked to account for an objective difficulty of timely diagnosis by both generalist or specialist clinicians. 12 More in details, when challenged by an undiagnosed RD patient, clinicians are often driven by textbook prototypical cases, as the rarity of the disease itself will prevent them from establishing a robust knowledge by direct experience. Such phenomenon will induce relevant cognitive bias in the diagnostic process of a RD, which can be synthesized in the general principle We recognize what we already know, historically attributed to Socrates (Vth Century B.C.). 10 Once the correct diagnosis is reached, patients acquire awareness on being affected by a condition lacking medical treatment effective to clear up their disease, requiring multi-disciplinary approach, and characterized by the multiple issues, as described in previous paragraph. 1, 2 Hence, several studies have reported a significant reduction in quality of life in persons with RD. 9, 13 The considerable burden exerted by RD on the lives of affected persons often results in a sense of social and psychological isolation. 9, 11 Finally, most RD exert a marked effect on survival. 8 A recent populationbased investigation reported that RD, when globally considered, accounted for 4.2% of the total years of life lost (YLLs) by the general population. 14 Noteworthy, mortality rates differ substantially across different RD, since some pathologies are associated to very early fatality events (<1 yr.-old), whereas other disorders show a longer survival, with diverse severity degrees.
Due to the aforementioned reasons, the presence of a rare disease determines a state of multidimensional vulnerability, which can be observed from different viewpoints (biological, clinical, social, psychological). These vulnerability factors are expected to contribute to the progressive deterioration in functioning across multiple physiological systems, thus triggering a condition of frailty, typical of RD patients. 1, 15 This trajectory towards frailty state is likely to represent a general features of RD, in spite of their clinical and pathophysiological heterogeneity.
Rare diseases in the elderly
For long time, RD have been traditionally regarded as being pertinent to the specialist in paediatrics, 2,14 rather than in geriatrics. 6 Such view is mainly based on the consideration that the vast majority of these disorders have a genetic etiology and a substantial proportion of them, such as most of complex congenital malformations, or several inborn errors of metabolism, are actually associated to very early onset (neonatal/infantile) and high mortality rates, resulting in a very short lifespan. On the other hand, it is of note that more than one third of RD have an onset in adulthood and that a growing number of pediatric patients with previously fatal RD now survive into adulthood, owing to early diagnosis and improvement of care options. 14 However, based on the severity of the manifestations and the marked impact on life expectancy of these disorders, the traditional viewpoint has long assumed RD as not being compatible with reaching geriatric age.
More profound observations of the RDrelated epidemiological profile suggest a quite different scenario, especially when analyzed in the context of the phenomenon of the demographic transition displayed by the high-income nations. Indeed, in countries characterized by the well-known global aging of the population, a non-negligible number of patients suffering from RD reach the geriatric age. In a preliminary survey carried out in Italian Apulia Region, on a sample of 69,902 Hospital Discharge Records, 927 patients aged >65 yrs. were found to be affected by a RD. 15 An epidemiological survey, based on Regional Registry of Rare Diseases in the population of Italian Veneto Region, reported an overall prevalence of 1.7 per thousand RD-affected subjects in the >65-yrs-old class, compared to an average value of 3.3 per thousand in the entire population, thus indicating a fraction of 9.1% of RD-affected subjects exceeding the threshold of geriatric age. 16 Such observation suggests that the generalized trend towards population aging, combined with specific advances in screening and treatment for some RD, will lead the specialist in geriatrics to face the challenge of managing elderly subjects with a RD.
A paradigmatic example is HHT, a rare autosomal-dominantly-inherited vascular dysplasia, showing a broadly heterogeneous clinical spectrum, in terms of onset age, clinical course, severity of manifestations. 17 The hallmark of HHT is the presence of multi-systemic arterio-venous malformations, abnormal direct connections between arterial and venous vascular bed, bypassing capillary network, responsible of number of symptoms/complications, including epistaxis, stroke, brain abscess, hypoxemia, gastrointestinal bleeding, high-output heart failure, portal hypertension. 18, 19 HHT may remain silent/oligosymptomatic for decades and then manifest with sudden life-threatening complications. 10 Life expectancy in HHT can be compatible with advanced age, showing on average a modest survival reduction, featuring two evident mortality peaks (an early peak, due to brain/lung complications, and a late peak at older ages, due to nosebleeds worsening). 20 As the proportion of HHT-affected individuals achieving the geriatric age threshold is currently growing, the specialist in geriatrics is expected to take in charge an increasing number of these subjects, who will come to his observation, presumably with different presentations. For example, some HHT patients can now benefit from appropriate preventive screening survey and avoid potentially fatal brain/lung complications, thus reaching geriatric age, while others display early-onset progressively uncontrollable nosebleeds and associated chronic debilitating iron-deficiency anemia, markedly affecting quality of life but still compatible with advanced age. 13, 21 Another subset of patients remains completely asymptomatic, thus experiencing disease onset only after 65 yrs.-old, and a last subgroup is characterized by a long diagnostic delay, with onset as young or middle-aged adults and attainment of correct diagnosis after geriatric age threshold. 10, 18 A similar scenario is expected to occur for other RD, such as haemophilia 22, 23 or Charcot-Marie-Tooth type 1. 24
Frailty in the elderly with rare disease
The specialist in geriatrics is very familiar with the concept of frailty. Frailty is characterized by a functional decline across multiple physiological systems, due to reduced homeostatic capacities, which usu- ally predisposes to increased risk of adverse clinical outcomes. 25 Given the growing relevance of RD also in the geriatric population, the frailty assessment will acquire a new perspective in elderly subjects with RD. It is plausible that the frailty associated with the condition of RD should be regarded in the context of the frailty status typical of the elderly. 15 Henceforth, frailty in an elderly with RD will derive from a complex interaction of agingrelated vulnerability with the RD-associated vulnerability which can occur at all levels (biological, clinical, psychological, social). As shown in Figure 1 , 26 in seniors with RD, the trend of the frailty profile is expected to display a sharper increase in relation to age, when compared with the basal situation of the general elderly population, thus mirroring the disease-related augmented disruption of functional capacity.
Review

Healthcare complexity in the elderly with rare disease
The presence of advanced age in an individual with RD adds considerable com-plexity in the healthcare management of these pathologies. For many RD, the phenotypic spectrum in the elderly still lacks reliable and full description, in that achieving the geriatric threshold was not compatible with these disorders until very recently. Furthermore, the clinical picture and the course of the RD are inserted in the typical pluri-pathology scenario of the geriatric age, thus displaying multiple concomitant diseases, which can arise as comorbidities (representing additional clinical manifestations, stemming from the RD, potentially worsening with age), or multimorbidities (representing long-term, aging-associated pathological entities, co-occurring in the same individual and apparently independent from the RD). 15, 22 Complexity of interactions between the primary rare disorder with co-morbidities and/or multi-morbidities can impact on healthcare at multiple levels. 15 The reported difficulties concerning diagnostic delay in RD are even more evident in the elderly with RD, since the concomitance of comorbidities and multimorbidities may obscure RD-related manifestations and complicate the diagnostic process. 3 The lack of effective therapeutic protocols afflicting RD is exacerbated in advanced age, due to ageingrelated pharmacokinetics and pharmacodynamics alterations, or to polypharmacyrelated issues. 22, 27 
Conclusions
In conclusion, the dramatic demographic changes that are occurring in the third millennium will permit to many RD to become compatible with advanced age. Thus, an increasing number of elderly patients with RD will seek medical care from geriatric specialists in the next future.
The challenge of the geriatrician of the III millennium will therefore consist in recognizing and managing these clinical entities, with associated comorbidities and multimorbidities, according to a global, holistic, and patient-centered approach. 
